Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Exclusion Criteria

• •Absolute granulocyte count =\<1,500/ul
• •Platelet count =\<75,000/ul
• •Serum creatinine \>= 2.0 mg/dl
• •Serum bilirubin
• •* \>= 2.0 mg/dl for bilateral treatment or lobar treatment
• •* \>= 3.0 mg/dl for single lesion which could be treated by segmental fusion
• •History of severe allergy or intolerance to any contrast media, narcotics, sedatives, or atropine
• •Bleeding, diathesis not correctable by usual forms of therapy
• •Severe peripheral vascular disease that would preclude catheterization
• •Portal hypertension with portal venous shunt away from the liver
• •Evidence of potential delivery greater than 16.5 mCi (30 Gy absorbed dose) of radiation to the lungs on either:
• •1. first TheraSphere administration; or
• •2. cumulative delivery of radiation to the lungs \> 30 Gy over multiple treatments
• •Evidence of any detectable Tc-99m MMA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow
• •Significant extrahepatic disease representing an imminent life-threatening outcome
• •Severe liver dysfunction (Childs' Classification C) or pulmonary insufficiency (requiring continuous oxygen therapy)
• •Active uncontrolled infection
• •Significant underlying medical or psychiatric illness
• •Pregnant women may not participate
• •Children may not participate